FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

					or sec	uon a	50(11) 0	ii iiie i	rivestinei	it Coi	npany Act t	JI 194	0						
Name and Address of Reporting Person* Fontenot Jason D.						2. Issuer Name and Ticker or Trading Symbol SANGAMO THERAPEUTICS, INC [SGMO]									heck all ap Dire	ationship of Reporting F c all applicable) Director Officer (give title below) SVP, Chief Scien		erson(s) to I 10% Ov Other (s	vner
(Last) (First) (Middle) C/O SANGAMO THERAPEUTICS, INC.						3. Date of Earliest Transaction (Month/Day/Year) 05/25/2023									^ belo			below)	
7000 MARINA BLVD.						4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street) BRISBANE CA 94005														X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to																		
		Table	I - No	n-Derivat							ons of Rule 1 posed of					ned			
1. Title of Security (Instr. 3) 2. Transacti Date (Month/Day)					/Year)	eemed Ition Date, h/Day/Year)				ies Acquired (A Of (D) (Instr. 3				icially d	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	m: Direct or rect (I)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
									Code	v	Amount	(A (D) or)	Price	Repor Trans			,	
Common Stock 05/25/2						023			F		1,029(1)		D	\$1.3	33 13	38,329(2)		D	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	ative Conversion Date Execution Date, if any			tion Date,	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable Expiration Date (Month/Day/Year)		te	Amo Secu Unde Deriv Secu	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	у	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership t (Instr. 4)
			Code	v	(A)	(D)	Date Exercisa	able	Expiration Date	Title	or Num of								

Explanation of Responses:

- 1. Represents shares underlying the portion of a restricted stock unit ("RSU") grant that vested on May 25, 2023, which were surrendered by the Reporting Person solely for mandatory tax withholding purposes using the Issuer's closing stock price on May 25, 2023 of \$1.33/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP"). This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise.
- 2. Includes: (a) 3,199 shares resulting from the May 25, 2023 vesting installment of the Reporting Person's February 25, 2022 RSU grant, and the remaining 29,597 shares will vest in successive equal quarterly installments through February 25, 2025, (b) 7,344 shares subject to the Reporting Person's February 25, 2021 RSU grant that will vest in one final installment on February 25, 2024 and (c) 42,750 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest as to one-quarter (1/4) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.

Remarks:

Jason D. Fontenot, by /s/ Ron A. Metzger, Attorney-in-Fact

05/30/2022

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.